Table 1.
Individual pairwise comparisons
| RAPID-axSpA and C-axSpAnd vs. | CZP Pooled vs. | Timepoint(s), weeks | Populationa |
|---|---|---|---|
| ABILITY-1 (n = 185) | ADA | 12 | bDMARD-naïve nr-axSpA (RAPID-axSpA n = 142; C-axSpAnd n = 299) |
| COAST-X (n = 303) | IXE |
16 52b |
bDMARD-naïve nr-axSpA (RAPID-axSpA n = 142; C-axSpAnd n = 299) |
| EMBARK (n = 215) | ETN | 12 | bDMARD-naïve nr-axSpA with symptom duration between > 3 months and < 5 years (C-axSpAnd n = 149) |
| GO-AHEAD (n = 198) | GOL | 16 | bDMARD-naïve nr-axSpA with disease duration ≤ 5 years (C-axSpAnd n = 139) |
| PREVENT (n = 555) | SEC |
16 52b |
nr-axSpAc (C-axSpAnd n = 317) |
ADA adalimumab, bDMARD biologic disease-modifying anti-rheumatic drug, CZP certolizumab pegol, ETN etanercept, GOL golimumab, IXE ixekizumab, nr-axSpA non-radiographic axial spondyloarthritis, SEC secukinumab
aSubgroup of C-axSpAnd and RAPID-axSpA trials included in order to match with the comparator population; bResults at 52 weeks only available in C-axSpAnd, but not RAPID-axSpA; cbDMARD-naïve nr-axSpA subgroup also analyzed where data were available (ASAS40 only)